Letter to the Editor
Copyright ©The Author(s) 2022.
World J Clin Oncol. Sep 24, 2022; 13(9): 758-761
Published online Sep 24, 2022. doi: 10.5306/wjco.v13.i9.758
Table 2 Main phase 3 trials evaluating adjuvant immunotherapy in non-small-cell lung cancer
Adjuvant NSCLC
Study
IO agent
Strategy
Objective
Status
Impower-010[7]Atezolizumab (anti-PD-L1)IO monoOS in selected PD-L1 populationFDA approved in II-IIIA NSCLC PD-L1+
KeyNote-091 (PEARLS)[8]Pembrolizumab (anti-PD-L1)IO monoDFSInterim analysis: positive in IB-IIIA NSCLC all corners
ANVIL[9]Nivolumab (anti-PD1)IO monoOS and DFSActive, not recruiting
NADIM-Adjuvant[10]Nivolumab (anti-PD-1)ChT + IODFSRecruiting
Mermaid-1[11]Durvalumab (anti-PD-L1)ChT + IODFS in MRD+Recruiting